Market Overview

Clinical Study Shows BioniCare® Reduces Pain of Carpal Tunnel Syndrome and Hand Arthritis


Non-drug pain relief now available for millions suffering from carpal tunnel syndrome and hand arthritis.

IRVINE, Calif. (PRWEB) August 15, 2018

VQ OrthoCare®, a leading provider of non-invasive, non-drug medical solutions focused on bone, joint and soft-tissue conditions, today announces the publication of a study showing BioniCare reduces pain and improves function for carpal tunnel syndrome and arthritis of the hand. The four month study, published this month in Orthopedics, shows that BioniCare relieves the symptoms of Carpal Tunnel Syndrome and Hand Osteoarthritis in as little as 4 weeks. BioniCare is a pulsed electrical signal applied to the hand by electrodes and a conductive glove.

In Carpal Tunnel patients, BioniCare reduced pain by 32%, paresthesia by 30% and improved the Physician's Global Score by 43%. BioniCare had an effect size greater than non-steroidal anti-inflammatory drugs (NSAIDs) across all measures. In all subjects, BioniCare reduced arthritis pain in the hand and thumb by 35%. Function was improved in all patients by 19% but improved by 23% in Carpal Tunnel patients.

The BioniCare Hand System is available by prescription only. The study can be found online at For more information, please visit or call VQ OrthoCare at 800-266-6969.

About VQ OrthoCare®:
Founded in 1989 and based in Irvine, Calif., VQ OrthoCare® is a leading manufacturer and provider of non-invasive medical solutions focused on bone, joint and soft-tissue conditions. VQ OrthoCare's commitment to treating patients with respect and supporting them in achieving optimum outcomes is unmatched in the industry. VQ OrthoCare's products include: BioniCare® Knee System, BioniCare Hand System, OActive™ 2, Catalyst Propel™ OA, Catalyst-Elite™, Catalyst-Propel™, FreeFlex™ OA; and the Eclipse™ Cervical Collar. VQ OrthoCare is registered with the U.S. Food and Drug Administration as a medical manufacturer and specification developer.

For the original version on PRWeb visit:

View Comments and Join the Discussion!